- Home
- NRIM vs AUTL Comparison
NRIM vs AUTL Comparison
Compare NRIM & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- AUTL
- Stock Information
- Founded
- NRIM 1990
- AUTL 2014
- Country
- NRIM United States
- AUTL United Kingdom
- Employees
- NRIM N/A
- AUTL N/A
- Industry
- NRIM Savings Institutions
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRIM Finance
- AUTL Health Care
- Exchange
- NRIM Nasdaq
- AUTL Nasdaq
- Market Cap
- NRIM 488.2M
- AUTL 415.2M
- IPO Year
- NRIM N/A
- AUTL 2018
- Fundamental
- Price
- NRIM $20.95
- AUTL $1.78
- Analyst Decision
- NRIM
- AUTL Strong Buy
- Analyst Count
- NRIM 0
- AUTL 5
- Target Price
- NRIM N/A
- AUTL $9.12
- AVG Volume (30 Days)
- NRIM 167.2K
- AUTL 4.8M
- Earning Date
- NRIM 10-22-2025
- AUTL 11-11-2025
- Dividend Yield
- NRIM 3.01%
- AUTL N/A
- EPS Growth
- NRIM 38.28
- AUTL N/A
- EPS
- NRIM 2.00
- AUTL N/A
- Revenue
- NRIM $175,041,000.00
- AUTL $29,934,000.00
- Revenue This Year
- NRIM N/A
- AUTL $641.63
- Revenue Next Year
- NRIM $8.63
- AUTL $109.21
- P/E Ratio
- NRIM $10.65
- AUTL N/A
- Revenue Growth
- NRIM 28.34
- AUTL 185.17
- 52 Week Low
- NRIM $15.92
- AUTL $1.11
- 52 Week High
- NRIM $25.05
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- NRIM 12.12
- AUTL 61.79
- Support Level
- NRIM $21.10
- AUTL $1.45
- Resistance Level
- NRIM $22.22
- AUTL $1.65
- Average True Range (ATR)
- NRIM 0.55
- AUTL 0.11
- MACD
- NRIM -0.23
- AUTL 0.05
- Stochastic Oscillator
- NRIM 0.00
- AUTL 97.85
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.